Infectious Disease Therapeutics Market Likely To Reach A Valuation Of Around USD 86.2 Billion By 2025:Key Participant Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd.

San Francisco, 31 December 2018,  Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2018 – 2025.

The global top6 infectious disease therapeutics market is expected to reach USD 86.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Access Full Research Report On Infectious Disease Therapeutics Market Analysis:www.grandviewresearch.com/industry-analysis/infectious-disease-therapeutics-market

Further Key Findings From the Report Suggest:

·         The HIV therapeutics segment held the largest revenue share in 2016 due to high number of HIV cases globally

·         North America dominated the global market owing to the strong reimbursement framework coupled with high adoption rate of treatments for infectious diseases

·         The HPV therapeutics segment is estimated to grow at the highest rate during the forecast period

·         Some of the key players areNovartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the top 6 infectious disease therapeutics market on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2014 - 2025)

·         HIV

o    Emtriva

o    Aptivus

o    Isentress

o    Lexiva/Telzir

o    Selzentry

o    Tivicay 

o    Atripla

o    Complera

o    Genvoya

o    Odefsey

o    Stribild

o    Truvada

o    Triumeq

o    Descovy

o    Vitekta

o    Others

·         Influenza

o    Relenza

o    Tamiflu 

o    Rapivab 

o    Others

·         TB

o    Sirturo

o    Others

·         Malaria

o    Coartem

o    Others

·         HPV

·         Hepatitis

Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:

www.grandviewresearch.com/press-release/global-infectious-disease-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Pediatric Vacciness Market Likely To Reach A Valuation Of Around USD 60.4 Billion By 2025:Key Participant GlaxoSmithKline plc, Pfizer, Inc.

San Francisco, 31 December 2018,  Pediatric Vaccines Market Analysis By Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate), By Application (Infectious Diseases, Cancer, Allergy), By Region, And Segment Forecasts, 2018 – 2025

The global pediatric vaccines market is expected to reach USD 60.4 billion by 2025 at an 11.7% CAGR, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market. 

Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.

Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.

Access Full Research Report On Pediatric Vaccines Market  Analysis:
www.grandviewresearch.com/industry-analysis/pediatric-vaccine-market

Further key findings from the report suggest:

·         The global pediatric vaccines market was estimated at USD 22.4 billion in 2016 and is expected to grow with a CAGR of 11.7% from 2017 to 2025

·         By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments

·         Conjugate vaccines formed the dominant technology segment in terms of revenue in 2016. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines

·         By application, the cancer segment is expected to witness the fastest growth with a CAGR of 12.6% owing to increasing prevalence of cancer and rising need for immunization against the disease

·         North America held the largest revenue share in 2016. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities

·         The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population

·         Key players such as GlaxoSmithKline plc; Pfizer, Inc.; SANOFI; and AstraZeneca dominated the global market for pediatric vaccines in 2016.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global pediatric vaccines market on the basis of type, technology, application, and region:

Type Outlook (Market Revenue in USD Billion, 2014 - 2025)

·         Monovalent

·         Multivalent

Technology Outlook (Market Revenue in USD Billion, 2014 - 2025)

·         Live Attenuated

·         Inactivated

·         Subunit

·         Toxoid

·         Conjugate

·         Others

Application Outlook (Market Revenue in USD Billion, 2014 - 2025)

·         Infectious disease

·         Cancer

·         Allergy

Regional Outlook (Revenue, USD Billion, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:

www.grandviewresearch.com/press-release/global-pediatric-vaccine-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Women’s Health Therapeuticss Market Is Poised To Reach USD 210.9 Billion By 2025:Key Participant Teva Pharmaceutical Industries Ltd

San Francisco, 04 October 2018, The global women’s health therapeutics market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Full Research Report On Women’s Health Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market

Further key findings from the report suggest:

·         By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases

·         Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs

·         North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases

·         Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players

·         Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global women’s health therapeutics market based on type and region:

Women’s Health Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)

·         Infection

·         Pregnancy

·         Oncology

o    Cervical Cancer

o    Ovarian Cancer

o    Uterine Cancer

o    Vaginal & Vulvar Cancer

Women’s Health Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

o    France

o    Spain

o    Italy

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-womens-health-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com